|
|
|
03.08.26 - 18:12
|
Pharma-Fusion: Keine Traum-Hochzeit (FAZ)
|
|
|
Die Börse reagiert besorgt auf die Gerüchte um eine Fusion von Astra-Zeneca und BMS. Denn es stellt sich die Frage, was der Mehrwert für den britischen Konzern sein sollte....
|
|
|
|
|
03.08.26 - 16:54
|
Pharmakonzerne: Astra-Zeneca erwägt Megafusion (FAZ)
|
|
|
Der britische Pharmakonzern hat offenbar Gespräche über einen Zusammenschluss mit dem US-Wettbewerber Bristol Myers Squibb geführt. Ein solches Vorhaben würde wohl auf hohe kartellrechtliche Hürden stoßen....
|
|
|
03.08.26 - 15:12
|
$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher" (ZeroHedge)
|
|
|
$400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
The Financial Times reported overnight that AstraZeneca has explored acquiring Bristol Myers Squibb in a potential megadeal that would create one of the world's largest drugmakers, with a combined market capitalization of nearly $400 billion.
The report cited people familiar with the matter, while both pharmaceutical giants declined to comment. Some Wall Street desks, however, are struggling to see the strategic rationale behind such a combination.
FT reported:
The companies have held discussions about a tie-up in recent months, according to people familiar with the matter. The talks could yield a deal in the near future but may be delayed or fall apart, the people said.
Bristol, valued at about $133 billion, would expand AstraZeneca's US presence but faces looming patent expirations for Eliquis and Opdivo, which together generate roughly half its sales. AstraZeneca, worth ab...
|
|
|
03.08.26 - 14:30
|
Chinese biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny (SCMP)
|
|
|
Wuxi AppTec, Asia's largest provider of contract pharmaceutical research, posted net income that smashed market expectations in the first half of the year amid strong demand tied to weight-loss and diabetes drugs, as well as gains in its US business.
Interim net profit attributable to the owners of the Shanghai-based drug contractor advanced 33.7 per cent to 11.08 billion yuan (US$1.64 billion) from a year earlier, surpassing a Bloomberg mean consensus estimate – drawn from a pool of 25 analysts......
|
|
|
|
|
|
|
|
|
|
|
03.08.26 - 10:18
|
Will AI healthcare be China′s new global growth engine? (SCMP)
|
|
|
Artificial intelligence (AI) has transformed healthcare for hundreds of millions of people in China.
AI-powered apps help them manage their health and seek care, while others help doctors better diagnose and treat their patients. AI analysis of routine scans detects cancers and other conditions physicians might have missed. Personalised cancer vaccines built on AI analysis will soon begin rolling off production lines in China. The country's leading tech companies have poured resources into......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.07.26 - 22:12
|
The Next AI Boom Is in Health Care and Robotics, Says Lux Capital′s Shakir (Bloomberg)
|
|
|
Recent disclosures from Anthropic and OpenAI have shifted the AI conversation from model capabilities to real-world deployment and security. Lux Capital Partner Deena Shakir says the next wave of AI innovation will be built on trust, partnerships and vertical applications like health care and robotics, not just more powerful foundation models. She joins Ed Ludlow on "Bloomberg Tech." (Source: Bloomberg)...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
